- 503Pharma
- Posts
- 503Pharma Weekly Compounding Pharmacy Roundup
503Pharma Weekly Compounding Pharmacy Roundup
Your trusted source for compounding pharmacy education, news and insights.
503Pharma .
July 22, 2026
STABILITY STUDY CONSORTIUM — FOUNDING MEMBER SPOTS
The 503Pharma Group Stability Study Consortium launches with 20 founding seats at $4,000/year — three Category 3 stability studies, extended BUD data you can reference. A single solo study costs more than this entire membership.
Full details and FAQs here. Key points:
- $4,000/year for at least 3 studies
- Limited to 20 founding members
- This is the lowest price this program will ever be
If interested, reply to this email and we’ll send you the enrollment details.
MEMBERS AREA
The 503Pharma Members Area, Redesigned
If you haven't logged into the 503Pharma Members Area lately, this is the week to take another look. Here's what you'll see when you log in.
What to compound next. A live shortage watchlist (70+ drugs, 25 with API supplier risk) alongside aggregated demand data from across the member network — 700+ formula searches in the last 30 days. When the network starts hunting for a formulation, you'll see it rising before it hits your phone lines.
Compliance for your state. Legislation, board actions, and comment deadlines filtered to your state (if data available), plus a quarterly pulse on FDA inspection activity.
Your tools, front and center. Formula library search, formula request tracking, and a "since your last visit" digest every time you log in.
All of it refreshed daily from FDA, the Federal Register, and pharmacy boards in 13 states (and counting).
Joining is free — 140+ pharmacy professionals and growing. Full formula library access comes with paid membership.
Explore the new 503Pharma Members Area: app.503pharma.com
This Week's Headlines
COMMITTEE MARKUP
Senate HELP Committee Takes Up the SAFE Drugs Act Today
The Senate Health, Education, Labor and Pensions Committee has the SAFE Drugs Act (S. 3794) on its executive session agenda for July 22 — alongside 12 other bills including the INSULIN Act and the Expedited Access to Biosimilars Act. A committee markup is the first concrete legislative step; the bill had been drawing page views on Congress.gov but had no scheduled action until now. If it advances, the reporting requirements for interstate compounding and the "essentially a copy" codification move closer to a floor vote.
GLP-1 LITIGATION
Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Outdated Comparisons
Novo Nordisk filed suit in U.S. District Court in New Jersey under the Lanham Act, alleging Lilly's nationwide Zepbound and Mounjaro ad campaigns compare the highest approved doses of Lilly's drugs to lower, now-superseded doses of Wegovy and Ozempic. One TV commercial cited in the complaint has received more than 700 million impressions since April. Novo's core argument: the FDA approved a 7.2 mg dose of Wegovy in March 2026, and trial data at that dose showed average weight loss of 47 pounds — comparable to the 50-pound figure Lilly's ads claim for Zepbound. Novo is seeking a permanent injunction, corrective advertising, and financial damages. Lilly said it stands behind its ads, citing the head-to-head SURMOUNT-5 trial.
PEPTIDE ACCESS
National Poll: 52% Support Legal Peptide Access Through a Pharmacy; 3% Oppose
A Mason-Dixon survey of 1,000 adults (July 13–16, commissioned by peptide-education site Peppies) found that among those with an opinion, support for obtaining peptides through a licensed pharmacy with a prescription ran 19 to 1 — though 49% of respondents said they'd heard nothing about peptides at all. Separately, the release cites an ECRI/ISMP white paper reporting grey-market peptide purity as low as 5% of labeled content, with arsenic and lead exceeding injectable-drug limits. The poll lands the day before the PCAC docket closes.
PCAC THIS WEEK
Peptide Vote Is Today
The PCAC comment docket (FDA-2025-N-6895) closes today at 11:59 PM ET. The meeting itself runs July 23–24 at White Oak with a live webcast — we covered FDA's briefing documents, which recommended against listing all seven peptides, in our July 9 issue.
GLP-1 OVERSIGHT
JAMA Study: Compounded GLP-1s Remain Widely Available at Brick-and-Mortar Clinics Post-Shortage
University of Colorado Anschutz researchers contacted 75 weight-loss clinics and medical spas in Oklahoma and West Virginia posing as customers. Published July 17 in JAMA Health Forum, the study found 56% of businesses offered compounded GLP-1 preparations containing added B vitamins, and nearly 10% offered oral GLP-1 compounds. Some identified supplier pharmacies lacked sterile compounding licenses or had recent disciplinary actions. The study examined marketing and sourcing, not product safety directly.
Clinical Trial Watch
What researchers study today is what prescribers ask you to compound tomorrow.
Trial | Phase / N | Sponsor | Why It Matters |
|---|---|---|---|
Phase 2 / 126 | U of Colorado Denver | GLP-1RA indication outside weight loss — if positive, opens a compounding-relevant use case in kidney disease | |
Phase 2 / 105 | Johns Hopkins | Head-to-head vs. the only approved BED drug; connects to the eating-disorder screening gap flagged in recent JAMA studies | |
Phase 2 / 20 | UT Health San Antonio | First controlled data on the muscle-loss concern driving prescriber interest in muscle-sparing peptide stacks |
Shortage Watch
Standing status from the FDA Drug Shortage Database.
Tobramycin Sulfate Injection — Newly posted July 17, 2026. Marked "To Be Discontinued" with high supply risk (3 manufacturers reporting). One of the workhorse aminoglycosides for ophthalmic and inhaled compounding; pharmacies relying on commercial tobramycin for fortified drops or nebulized preparations should verify alternative sourcing now.
Travoprost Ophthalmic Solution — Posted July 7, 2026, also marked for discontinuation. High supply risk. Nine manufacturers on file but only two NDCs in shortage reporting. Compounders with ophthalmic programs should monitor glaucoma treatment formulary implications.
Liraglutide Injection — Remains on the shortage list. This is the one GLP-1 that 503B outsourcing facilities can still legally compound from bulk substances, since shortage-list presence provides the statutory basis. The proposed exclusion rule, if finalized, would remove that pathway even in future shortages.
What We're Watching
July 22 — PCAC public comment docket (FDA-2025-N-6895) closes at 11:59 PM ET.
July 23–24 — PCAC meeting, FDA White Oak Campus, Silver Spring, MD. Seven peptides under 503A bulks list review. Live webcast available.
July 30 — Extended comment deadline for 503B GLP-1 exclusion proposed rule (docket FDA-2018-N-3240).
Coming days — Novo Nordisk indicated it will file for a preliminary injunction against Lilly's GLP-1 comparison ads if they are not voluntarily pulled.
August 29 — Self-Administered Drug Exclusion List update effective (NGS, A53021). Review if your formulary includes Part B infusible drugs near the SAD boundary.
✉️ That’s your 503Pharma weekly digest. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.
The 503Pharma Team